GW Parma’s Sativex Launched in UK
This week Sativex was given a green signal by the UK authorities. Sativex is a medicine used for the cure of Multiple Sclerosis. It is a cannabis-based medicine, which is available in the form of a mouth spray.
The drug was launched on Monday in the UK and will be sold by Bayer.
It is being produced by GW Pharmaceuticals. Chief Executive of the Company, Dr. Geoffrey Guy reveals that it is the first cannabis based medicine, which has been given consent by having a full pharmaceutical process at anyplace in the world. This drug is also the first plant based medicine, which has been given a nod in the recent times.
Dr. Guy also revealed that the Company has launched its first such range of products comprising of cannabis plant.
Sativex is sprayed under the tongue and is similar in volume to an asthma inhaler. One mouth spray can give 90 sprays. A patient of Multiple Sclerosis administers around eight sprays a day.
Patients in UK had an access to the drug since 2005, but on a "named patient" basis, in which they had to ask the manufacturer for supply of the drug. Now, the drug will be available across the country.
New Zealand News
- Porsche reportedly developing electric version of 718 sports car
- Tesla Model Y Performance becomes little bit more expensive to order in China
- Porsche’s recently unveiled Mission R Concept previews electric race cars of future
- Chinese manufacturer GAC’s Aion V e-SUV can charge 0-80% in just 8 minutes
- Oshidori International exits Japanese casino race, citing serious ethical irregularities
- Plug-in cars’ share grows to 32% in Netherlands in September 2021
- Italian motorcycle racer Valentino Rossi enters e-bike business with VR46 MTB range
- Micro Mobility shows off production version of Microlino 2.0 and 3-wheeled e-scooter
- Chinese electric motorcycle maker Evoke Motorcycles to set up shops in Spain
- TenneT adds more electric BMWs to study use of EVs to support power grids